James Barrett - Loxo Oncology Independent Director
Director
Dr. James E. Barrett Ph.D. is an Independent Director of Loxo Oncology Inc. since April 2014. Since 2001 he has served on the board of directors since April 2014. Since 2001 he has served as a General Partner of New Enterprise Associates or NEA a VC firm where he specializes in biotechnology and works with members of NEAs healthcare investment group on medical devices healthcare information systems and healthcare services companies. Prior to joining NEA from 1997 to 2001 Dr. Barrett founded and served as Chairman and Chief Executive Officer at Sensors for Medicine and Science a medical device company. In addition to serving on our board of directors Dr. Barrett currently serves on the boards of several biopharmaceutical and biotechnology companies including Clovis Oncology Inc. Roka Bioscience Inc. GlycoMimetics Inc. Zosano Pharma Corporation and Supernus Pharmaceuticals Inc. He also serves on the board of directors of several private companies. He previously served on the boards of Inhibitex Inc. from 2002 to 2012 and Targacept Inc. from 2002 to 2013 since 2014.
| Age | 71 |
| Tenure | 10 years |
| Professional Marks | MBA |
| Phone | 203 653-3880 |
| Web | www.loxooncology.com |
Loxo Oncology Management Efficiency
Loxo Oncology's management efficiency ratios could be used to measure how well Loxo Oncology manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Glenn Corlett | Rocky Brands | 73 | |
| Patricia Mueller | Dave Busters Entertainment | 54 | |
| Morton Erlich | Skechers USA | 75 | |
| Mark Ain | KVH Industries | 74 | |
| Curtis Loveland | Rocky Brands | 67 | |
| Robert Moore | Rocky Brands | 66 | |
| Hong Du | Weibo Corp | 45 | |
| Geyer Kosinski | Skechers USA | 54 | |
| John Toms | Eastern Co | N/A | |
| Bruce Ryan | KVH Industries | 73 | |
| Yichen Zhang | Weibo Corp | 50 | |
| Stanley Honey | KVH Industries | 62 | |
| Michael Griffith | Dave Busters Entertainment | 60 | |
| Charles Henry | Eastern Co | 68 | |
| Frank Tang | Weibo Corp | 48 | |
| Kevin Sheehan | Dave Busters Entertainment | 64 | |
| Harley Rouda | Rocky Brands | 53 | |
| Hamish Dodds | Dave Busters Entertainment | 60 | |
| Charles Trimble | KVH Industries | 76 | |
| James Stewart | Rocky Brands | 80 | |
| Pehong Chen | Weibo Corp | 59 | |
Management Performance
| Return On Equity | -0.63 | |||
| Return On Asset | -0.0059 |
Loxo Oncology Leadership Team
Elected by the shareholders, the Loxo Oncology's board of directors comprises two types of representatives: Loxo Oncology inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Loxo. The board's role is to monitor Loxo Oncology's management team and ensure that shareholders' interests are well served. Loxo Oncology's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Loxo Oncology's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jacob Naarden, VP of Corporate Devel. and Strategy | ||
| James Barrett, Independent Director | ||
| Timothy Mayleben, Independent Director | ||
| Jennifer Low, Chief Medical Officer | ||
| Joshua Bilenker, President CEO, Director | ||
| Avraham Naider, Independent Director | ||
| Lori Kunkel, Director | ||
| David Bonita, Independent Director | ||
| Jennifer Burstein, Vice President - Finance, Principal Financial Officer and Principal Accounting Officer | ||
| Keith Flaherty, Director | ||
| Steven Elms, Independent Director | ||
| Alan Fuhrman, Independent Director | ||
| Steven Harr, Independent Director | ||
| Sara Slifka, Sr. Director of Operations | ||
| Nisha Nanda, VP of Devel. Strategy |
Loxo Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Loxo Oncology a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.63 | |||
| Return On Asset | -0.0059 | |||
| Profit Margin | (43.49) % | |||
| Operating Margin | (50.33) % | |||
| Current Valuation | 6.56 B | |||
| Shares Outstanding | 30.75 M | |||
| Shares Owned By Insiders | 3.70 % | |||
| Shares Owned By Institutions | 92.93 % | |||
| Number Of Shares Shorted | 1.03 M | |||
| Price To Earning | (20.33) X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Other Consideration for investing in Loxo Stock
If you are still planning to invest in Loxo Oncology check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Loxo Oncology's history and understand the potential risks before investing.
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |